Discovery of 4H-Chromen-4-one Derivatives As a New Class of Selective Rho Kinase (ROCK) Inhibitors, Which Showed Potent Activity in Ex Vivo Diabetic Retinopathy Models

Lanying Zhao,Yueshan Li,Yujiao Wang,Zeen Qiao,Zhuang Miao,Jiao Yang,Luyi Huang,Chenyu Tian,Linli Li,Danian Chen,Shengyong Yang

DOI: https://doi.org/10.1021/acs.jmedchem.9b01143

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:Diabetic retinopathy (DR) is a major cause of blindness, and there is a lack of effective treatment at present. Rho-associated coiled-coil containing serine/threonine protein kinases (ROCKs) have recently been suggested as potential targets for the DR treatment. We herein report the discovery of 4H-chromen-4-one derivatives as a new class of ROCK inhibitors. Structure-activity relationship analyses led to the identification of the most active compound, 4-(dimethylamino)-N-(3-{2-[(4-oxo-4H-chromen-7-yl)oxy]acetamido}phenyl) (12j). This compound showed excellent kinase selectivity for ROCK I and ROCK II against 387 other kinases. In retinal explants, compound 12j protected retinal neurons from high glucose-induced oxidative stress and apoptosis-mediated cell death. Furthermore, 12j administration suppressed the improper proliferation of Müller cells and promoted the regression of vascular vessels in retinal explants cultured in a high glucose microenvironment. Collectively, our data suggest that 12j could be a potential lead compound for the treatment of DR, hence deserving further in-depth studies.